A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
NCT ID: NCT06147063
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
243 participants
INTERVENTIONAL
2023-11-27
2025-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
NCT05037097
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
NCT04668339
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
NCT05472038
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
NCT04847102
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
NCT06354998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The duration of each participant's involvement in the study will be approximately 12 months following administration of study vaccination.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: dosage 1 of AZD9838 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD9838.
AZD9838
Intramuscular (IM) injection.
Arm 2: dosage 2 of AZD9838 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD9838.
AZD9838
Intramuscular (IM) injection.
Arm 3: licensed mRNA vaccine 18 to 64 years of age
Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
Licensed mRNA vaccine
Intramuscular (IM) injection.
Arm 4: dosage 1 of AZD6563 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD6563.
AZD6563
Intramuscular (IM) injection.
Arm 5: dosage 2 of AZD6563 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD6563.
AZD6563
Intramuscular (IM) injection.
Arm 6: dosage 1 of AZD6563 65 years of age and older
Participants will receive 1 intramuscular dose of AZD6563.
AZD6563
Intramuscular (IM) injection.
Arm 7: dosage 2 of AZD6563 65 years of age and older
Participants will receive 1 intramuscular dose of AZD6563.
AZD6563
Intramuscular (IM) injection.
Arm 8: licensed mRNA vaccine 65 years of age and older
Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
Licensed mRNA vaccine
Intramuscular (IM) injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD9838
Intramuscular (IM) injection.
Licensed mRNA vaccine
Intramuscular (IM) injection.
AZD6563
Intramuscular (IM) injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-reported History of SARS-CoV-2 infection at least 6 months prior to study vaccination AND/OR prior completion of primary series vaccination against COVID-19, with the final dose received at least 6 months prior to study vaccination
* Negative SARS-CoV-2 RT-PCR test at Visit 1
* Body mass index (BMI) of \<35 kg/m2 at screening
* Medically stable - according to the judgement of the investigator, hospitalization within the study is not anticipated and participant is likely to remain in the study through the end of the protocol specified follow-up.
Exclusion Criteria
* History of hypersensitivity to any component of the study vaccination, severe adverse reaction associated with a vaccine and/or severe allergic reaction
* Positive COVID-19 test result within 6 months of Visit 1
* Receipt of licensed, authorized, or investigational COVID-19 vaccines in the 6 months prior to administration of study intervention or expected receipt through completion of Visit 5.
* Receipt of any COVID-19 monoclonal antibody (licensed or investigational) within 3 months or receipt of immunoglobulin (non-COVID related) or blood products within 6 months prior to administration of study intervention, or expected receipt during the study
* Receipt of any licensed or investigational vaccine (other than licensed influenza vaccines or non-study COVID-19 vaccines) within 30 days prior to Visit 1 or expected receipt prior to completion of Visit 4. Licensed influenza vaccines are permitted beginning \> 14 days before and \> 14 days after administration of study intervention.
* Previous history of myocarditis or pericarditis
* Woman who are pregnant, lactating, or of child-bearing potential and not using a contraception or abstinence from at least 4 weeks prior to study vaccination and until at least 6 months after study vaccination
* Lab values above ULN (Serum creatinine, AST, ALT), below LLN (hemoglobin, WBC, Platelet count) or any lab value that in the opinion of the investigator is clinically significant or might confound analysis of the study results. Participants with laboratory values outside of the normal range may have the abnormal test repeated within the screening window and if the values are normal, then the participant can be randomized. If the repeated value remains outside of the normal range but it is not felt to be clinically significant by the Investigator, the case can be discussed with the AstraZeneca study physician and if they both agree the value is not clinically significant, the participant can be randomized
* History of malignancy within 5 years (treated non-melanoma skin cancer and locally treated cervical cancers allowed)
* Known or suspected congenital or acquired immunodeficiency
* Known or suspected autoimmune conditions as determined by history and /or physical examination
* Active infection with hepatitis B or C
* Troponin I levels above the normal range at the screening visit
* History of hypersensitivity to kanamycin or any aminoglycoside antibiotics (eg, neomycin, streptomycin, tobramycin, and gentamicin).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Long Beach, California, United States
Research Site
Rolling Hills Estates, California, United States
Research Site
Chicago, Illinois, United States
Research Site
Wichita, Kansas, United States
Research Site
North Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8670C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.